For the Inventor, By the Inventor

Enter assignee name

Mountain View, CA, United States of America

Amunix Operating Inc.

Calculating rank

USPTO Granted Patents = 24

CIPO Patents = 5

EPO Patents = 8

Trademarks = 1

Forward Citations = 543

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Volker Schellenberger (24 out of 68 patents)

Willem P Stemmer (21 out of 40 patents)

Chia-wei Wang (21 out of 25 patents)

4. Joshua A Silverman (17 out of 56 patents)

5. Nathan C Geething (16 out of 20 patents)

6. Benjamin Spink (11 out of 15 patents)

7. Jeffrey L Cleland (10 out of 47 patents)

8. Wayne To (7 out of 18 patents)

9. Mikhail Popkov (4 out of 11 patents)

10. Michael D Scholle (4 out of 5 patents)

11. Nathaniel C Gordon (4 out of 7 patents)

12. Andreas Crameri (4 out of 23 patents)

13. Bryant McLaughlin (2 out of 3 patents)

14. David Bruce Baldwin (1 out of 6 patents)

15. John Michael Beals (1 out of 10 patents)

24 patents: Sort by Forward Citations

1. 10172953 - XTEN conjugate compositions and methods of making same (2019-01-08),

2. 10035839 - Blood glucose lowering compound (2018-07-31),

3. 10000543 - Glucose-regulating polypeptides and methods of making and using same (2018-06-19),

4. 9976166 - Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same (2018-05-22),

5. 9938331 - Biologically active proteins having increased in vivo and/or in vitro stability (2018-04-10),

6. 9926351 - Extended recombinant polypeptides and compositions comprising same (2018-03-27),

7. 9849188 - Growth hormone polypeptides and methods of making and using same (2017-12-26),

8. 9758776 - Coagulation factor IX compositions and methods of making and using same (2017-09-12),

9. 9540430 - Glucose-regulating polypeptides and methods of making and using same (2017-01-10),

10. 9376672 - Coagulation factor IX compositions and methods of making and using same (2016-06-28),

11. 9371369 - Extended recombinant polypeptides and compositions comprising same (2016-06-21),

12. 9249211 - Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same (2016-02-02),

13. 9168312 - Growth hormone polypeptides and methods of making and using same (2015-10-27),

14. 9062299 - Coagulation factor IX compositions and methods of making and using same (2015-06-23),

15. 8957021 - Glucose-regulating polypeptides and methods of making and using same (2015-02-17),

Company Overview

Amunix Operating Inc., based in Mountain View, California, specializes in the development of innovative biopharmaceuticals. The company focuses on advancing protein therapeutics, particularly through its proprietary technology platform that enables the creation of next-generation therapeutics. Amunix is dedicated to addressing significant unmet medical needs by leveraging its expertise in protein engineering and drug delivery systems, aiming to improve patient outcomes in various therapeutic areas.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

24 Patents

#127 in Mountain View, CA

#3,290 in California

#13,895 in US

#26,686 in the World

Mountain View, CA, United States of America

Amunix Operating Inc.

Forward Citations = 543

24 inventors:

Volker Schellenberger (24 out of 68 patents)

Willem P Stemmer (21 out of 40 patents)

Chia-wei Wang (21 out of 25 patents)

4. Joshua A Silverman (17 out of 56 patents)

5. Nathan C Geething (16 out of 20 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Amunix Operating Inc.. Retrieved from https://idiyas.com/company/amunix-operating

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…